Optimal treatment duration of bevacizumab (BEV) combined with carboplatin and paclitaxel in patients (pts) with primary epithelial ovarian (EOC), fallopian tube (FTC) or peritoneal cancer (PPC): A multicenter open-label randomized 2-arm phase 3 ENGOT/GCIG trial of the AGO Study Group, GINECO, and NSGO (AGO-OVAR 17/BOOST, GINECO OV118, ENGOT Ov-15, NCT01462890).

Jacobus Pfisterer,Florence Joly,Gunnar B. Kristensen,Joern Rau,Sven Mahner,Patricia Pautier,Ahmed El-Balat,Jean-Emmanuel Kurtz,Ulrich Canzler,Jalid Sehouli,Martin Heubner,Andreas D. Hartkopf,Klaus Baumann,Annette Hasenburg,Lars Ch. Hanker,Antje Belau,Barbara Schmalfeldt,Dominik Denschlag,Tjoung-Won Park-Simon,Philipp Harter

Optimal treatment duration of bevacizumab (BEV) combined with carboplatin and paclitaxel in patients (pts) with primary epithelial ovarian (EOC), fallopian tube (FTC) or peritoneal cancer (PPC): A multicenter open-label randomized 2-arm phase 3 ENGOT/GCIG trial of the AGO Study Group, GINECO, and NSGO (AGO-OVAR 17/BOOST, GINECO OV118, ENGOT Ov-15, NCT01462890).

2021

5501Background: GOG-0218 established the addition of BEV 15 mg/kg every 3 weeks (q3w) for 15 months to standard front-line chemotherapy for advanced ovarian cancer, but the optimal BEV duration rem...

Keywords:

in patient
Bevacizumab
Oncology
Medicine
Peritoneal cancer
optimal treatment
Chemotherapy
Carboplatin
Internal medicine
Paclitaxel
Fallopian tube

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations